Mr. Jeff Ruby reports

NEWTOPIA LAUNCHES "GLP-1 SUSTAIN" PROGRAM TO AFFORDABLY PRESERVE AND EXTEND VALUABLE HEALTH BENEFITS OF NOVEL WEIGHT LOSS DRUGS

Newtopia Inc. is rolling out GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey -- once a user first encounters a weight-loss plateau and even if users cease taking the medication entirely.

In so doing, Newtopia's GLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long lasting and that the significant costs to invest in them may in fact yield a positive return on investment for payers, employers, value-based providers and patients.

Newtopia's habit change platform is already proven for its unrivalled ability to generate and maintain high levels of user engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70 per cent of its participants as actively engaged at 12 months, and over 60 per cent engaged at 24 months.

Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3 per cent of the preprogram weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant.

Leveraging this very same habit change platform, Newtopia's GLP-1 Sustain combines genetic testing for risk factors and key behaviours with individualized live coaching, curated content and remote monitoring from smart devices to help any GLP-1 user identify, develop and internalize constructive lifestyle habits necessary to sustain weight loss, health and well-being over time -- whether users remain on, or ultimately stop taking these medications.

"We are very excited to bring our proven engagement and habit change value-proposition to the GLP-1 juggernaut," says Newtopia founder and chief executive officer, Jeff Ruby. "We know from experience that we can produce sustainable habit change in this patient population -- just as we have done for every other population we serve."

GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of approximately $10,000-plus per participant (for example the average annual cost of GLP-1 medications of approximately $12,000 replaced postplateau, or if users cease the medication, with the average annual value-based cost of Newtopia of approximately $750).

At less than one-10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.

"Newtopia's GLP-1 Sustain may be the missing piece we need to resolve a cost-benefit conundrum in one of the fastest-growing drug markets of all time," said Greg Steinberg, MD -- cardiologist, former head of clinical innovation at Aetna, and former chief executive officer of ActiveHealth Management. "Payers and employers must balance the urgent need to produce meaningful health outcomes in their populations with the practical need to produce positive returns on their spend. If the weight does not stay off, the expense of GLP-1s and related drugs is hard to justify. But if Newtopia helps users sustain their weight loss, especially when they cycle off the drug protocol, payers, employers and providers can begin to rationalize prescribing and funding greater access to these medications."

About Newtopia Inc.

Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow or reverse chronic disease while reducing health care costs. The platform leverages genetic, social and behavioural insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centred approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange and is quoted in the United States on the OTCQB Venture Market.

We seek Safe Harbor.